

Guy Cavet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11437135/publications.pdf>

Version: 2024-02-01

21
papers

3,073
citations

394421

19
h-index

713466

21
g-index

22
all docs

22
docs citations

22
times ranked

5431
citing authors

#	ARTICLE	IF	CITATIONS
1	Distinct clonal evolution of B-cells in HIV controllers with neutralizing antibody breadth. <i>ELife</i> , 2021, 10, .	6.0	16
2	Repertoire Builder: high-throughput structural modeling of B and T cell receptors. <i>Molecular Systems Design and Engineering</i> , 2019, 4, 761-768.	3.4	62
3	Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection. <i>Cell</i> , 2019, 177, 1566-1582.e17.	28.9	153
4	Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens. <i>Clinical Immunology</i> , 2018, 187, 37-45.	3.2	86
5	A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study. <i>Modern Rheumatology</i> , 2015, 25, 344-349.	1.8	17
6	A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. <i>Rheumatology</i> , 2013, 52, 1202-1207.	1.9	79
7	Efficacy and safety of mavrilmumab in subjects with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1445-1452.	0.9	149
8	An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. <i>Rheumatology</i> , 2013, 52, 839-846.	1.9	59
9	Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use. <i>Current Medical Research and Opinion</i> , 2013, 29, 85-92.	1.9	24
10	Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis. <i>PLoS ONE</i> , 2013, 8, e60635.	2.5	146
11	Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1692-1697.	0.9	107
12	Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. <i>Arthritis Care and Research</i> , 2012, 64, 1794-1803.	3.4	149
13	Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 70, 415-424.	2.8	82
14	Inferring the functional effects of mutation through clusters of mutations in homologous proteins. <i>Human Mutation</i> , 2010, 31, 264-271.	2.5	48
15	<i>In vivo</i> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models. <i>Clinical Cancer Research</i> , 2009, 15, 4649-4664.	7.0	434
16	Molecular predictors of response to a humanized anti-“insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2110-2121.	4.1	78
17	Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes. <i>Molecular Cancer Research</i> , 2009, 7, 511-522.	3.4	201
18	Functional Genomics Identifies ABCC3 as a Mediator of Taxane Resistance in HER2-Amplified Breast Cancer. <i>Cancer Research</i> , 2008, 68, 5380-5389.	0.9	102

#	ARTICLE	IF	CITATIONS
19	Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. <i>Nature Medicine</i> , 2007, 13, 1070-1077.	30.7	542
20	Comment on "The Consensus Coding Sequences of Human Breast and Colorectal Cancers". <i>Science</i> , 2007, 317, 1500-1500.	12.6	53
21	Epithelial versus Mesenchymal Phenotype Determines <i>In vitro</i> Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2005, 11, 8686-8698.	7.0	485